La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-TROP-2 immunotherapeutics in
Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-nectin-4 immunotherapeutics in
CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CCR8 immunotherapeutics in R&D: Pipeline
EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-EpCAM immunotherapeutics in
5T4: a delicate target for sophisticated payload delivery – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of the free report Pipeline of 5T4-Targeted Immunotherapies to showcase its newest service of pipeline
B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-B7-H4 immunotherapeutics in R&D: Pipeline
Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-mesothelin immunotherapeutics
c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-c-Met immunotherapeutics in R&D:
STUTTGART, Germany I August 14, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of drug modality technologies available for a R&D organization. La Merie Publishing
STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Her3 immunotherapeutics in R&D: Pipeline of Her3-Targeted Immunotherapies. This competitive intelligence report about Her3-Targeted Immunotherapies provides a
